Wednesday, July 25, 2018

Amgen Backed Alector Adds $133M

South San Francisco-based Alector, a biotechnology company focused on finding treatments for neurodegenerative diseases and cancer, announced Wednesday that it has raised $133M in a Series E funding round. The company--which is backed by Thousand Oaks-based Amgen--said the funding came from Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Perceptive Advisors, Casdin Capital, Polaris Partners, OrbiMed, MRL Ventures, GV, the Dementia Discovery Fund, Mission Bay Capital, Amgen Ventures, and others. Alector said the financing will go to advance its clinical programs and expand the company's discovery platform. More information »